



Stereotactic Body Radiotherapy

Guest Editor:

Dr. Gianluca Ingresso

Radiation Oncology Section,
Department of Medicine and
Surgery, University of Perugia,
06129 Perugia, Italy

Deadline for manuscript
submissions:

closed (10 September 2021)

Message from the Guest Editor

Dear Colleagues,

Stereotactic radiotherapy (SRT) is a treatment option curing cancer that creates highly conformal dose distributions with steep dose gradients, using advanced planning and treatment equipment. Stereotactic radiotherapy allows for the safe delivery of high doses of radiation to the target lesion, while sparing the surrounding critical organs. More specifically, in clinical practice, it is a useful tool in patients affected by limited metastatic disease, defined as an “oligometastatic state”, which is considered as an intermediate state between localized and widespread cancer. In patients with a limited number of metastases from a variety of primary sites, it seems that SRT might improve overall survival and disease-progression-free survival, with a limited cost in terms of treatment-related morbidity. SRT is also under investigation for the treatment of primary tumors, instead of surgery or conventional radiotherapy, such as for curing lung cancer and prostate cancer. For these reasons, this Special Issue will explore the use of stereotactic radiotherapy in the therapy of solid tumors.

Dr. Gianluca Ingresso

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory
Medicine and Pathobiology,
Department of Surgery,
University of Toronto, 6 Queens
Pk Crescent W.F, Toronto, ON
M5S 3H2, Canada

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank: CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)